Sierra Bancorp (NASDAQ:BSRR), the parent company of Bank of the Sierra, announced strong unaudited financial results for the first quarter of 2026 on Monday, reporting a 47% increase in diluted earnings per share compared to the same period last year.
Repay Holdings (NASDAQ:RPAY) released preliminary, unaudited financial results for the first quarter of 2026 on Monday, April 27, while simultaneously raising its full-year profitability outlook.
Business First Bancshares (NASDAQ:BFST), the parent company of b1BANK, reported its first-quarter 2026 financial results on Monday, highlighting a period of significant expansion following its recent merger activity.
Bank of Marin Bancorp (NASDAQ:BMRC) reported a strong return to profitability for the first quarter of 2026 on Monday, posting net income of $8.5 million.
Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).
AbbVie (NYSE:ABBV) announced on Monday, April 27, 2026, that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa).
Norwood Financial (NASDAQ:NWFL), the parent company of Wayne Bank, announced its financial results for the first quarter of 2026 on Monday, a period defined by the successful closing and integration of Presence Bancshares.
Thermo Fisher Scientific (NYSE:TMO) announced on Monday that it has entered into a definitive agreement to sell its microbiology business to Astorg, a prominent pan-European private equity firm.
Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii).
CorMedix (NASDAQ:CRMD) announced positive topline results on Monday from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for the prevention of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant (HSCT) patients.
Alterity Therapeutics (NASDAQ:ATHE) announced on Monday that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a second Type C meeting regarding its ATH434 Phase 3 program.
Intellia Therapeutics (NASDAQ:NTLA) today announced positive topline results from its pivotal Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR-based gene editing therapy for patients with hereditary angioedema (HAE).
